Jove
Visualize
Contact Us

Related Experiment Videos

Misconceptions about calcimimetics.

E F Nemeth1

  • 1NPS Pharmaceuticals, Inc., 101 College Street, South Tower, Suite 800, Toronto, ON M5G 1L8 Canada. enemeth@npsp.com

Annals of the New York Academy of Sciences
|July 13, 2006
PubMed
Summary

Calcimimetics, like cinacalcet, target the calcium receptor to reduce parathyroid hormone secretion. This discovery offers valuable insights for developing new drugs and advancing medical research.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Calcimimetic and Calcilytic Drugs: Feats, Flops, and Futures.

Calcified tissue international·2015
Same author

Allosteric modulators of the extracellular calcium receptor.

Drug discovery today. Technologies·2013
Same author

Parathyroid hormone fragments inhibit active hormone and hypocalcemia-induced 1,25(OH)2D synthesis.

Kidney international·2007
Same author

The parathyroid polyhormone hypothesis revisited.

Kidney international. Supplement·2006
Same author

Summary--calcium receptors: potential targets for novel treatments for skeletal disease.

Journal of musculoskeletal & neuronal interactions·2005
Same author

Calcimimetic and calcilytic drugs: just for parathyroid cells?

Cell calcium·2004
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Area of Science:

  • Pharmacology
  • Endocrinology
  • Drug Discovery

Background:

  • Calcimimetics are compounds that activate the calcium receptor.
  • Phenylalkylamines, such as cinacalcet, represent a key class of small molecule calcimimetics.
  • Cinacalcet is a selective positive allosteric modulator of the parathyroid calcium receptor.

Purpose of the Study:

  • To review the discovery of calcimimetics and their target receptor.
  • To extract lessons applicable to medical research and novel drug discovery.
  • To highlight the significance of cinacalcet in treating hyperparathyroidism.

Main Methods:

  • Literature review of calcimimetic research.
  • Analysis of cinacalcet's mechanism of action.
  • Examination of regulatory approval pathways for novel therapeutics.

Main Results:

  • Cinacalcet is the first approved calcimimetic for hyperparathyroidism in end-stage renal disease.
  • The study underscores the therapeutic potential of targeting the calcium receptor.
  • Understanding calcimimetic action provides a model for drug development.

Conclusions:

  • The development of calcimimetics demonstrates successful targeted drug discovery.
  • Lessons learned can inform future research into receptor modulators.
  • Further exploration of calcimimetic mechanisms may yield new therapeutic strategies.

Related Experiment Videos